Female hypergonadotropic hypogonadism

Female hypergonadotropic hypogonadism is an endocrine condition characterised by reduced ovarian estrogen secretion associated with a compensatory increase in FSH and LH, reflecting a primary impairment of ovarian function. From a pathophysiological perspective, the defect lies within the ovary, which is no longer able to ensure effective folliculogenesis, adequate steroidogenesis or a proportionate response to gonadotropin stimulation. The resulting loss of normal negative feedback on the hypothalamic-pituitary axis causes persistent central activation that nevertheless fails to restore sufficient gonadal function.

This definition describes an endocrine phenotype rather than a single disease. In clinical practice, female hypergonadotropic hypogonadism encompasses conditions ranging from gonadal dysgenesis and chromosomal abnormalities during development to primary ovarian insufficiency in young adult women, including autoimmune, genetic and iatrogenic forms. Its clinical impact is not limited to amenorrhea and infertility, but also involves pubertal development, bone health, sexual function, cardiovascular risk, psychological wellbeing and quality of life, making accurate aetiological assessment and long-term endocrine management necessary.

The epidemiology of female hypergonadotropic hypogonadism is heterogeneous because it reflects the diversity of its causes and ages at onset. In adolescents and young women, a substantial proportion of cases results from chromosomal abnormalities, gonadal dysgenesis or genetic defects that impair the development and survival of the follicular pool. In adult women of reproductive age, the hypergonadotropic phenotype more frequently corresponds to primary ovarian insufficiency, namely the loss or marked reduction of follicular function before the age of 40. Within this subgroup, overall prevalence is not negligible, with estimates varying according to the definition used, the population studied and the sensitivity of diagnostic pathways.

Age distribution is closely related to pathogenesis. Forms developing before or during puberty typically present with delayed puberty, absent breast development or primary amenorrhea and suggest congenital or chromosomal causes. Forms emerging after menarche are more likely to present with progressive oligomenorrhea, secondary amenorrhea, infertility or symptoms of hypoestrogenism, indicating accelerated follicular loss or progressive ovarian dysfunction. This temporal gradient is clinically relevant because it allows the presentation to be interpreted correctly and directs suspicion towards different mechanisms.

The main risk factors include abnormalities of the X chromosome, particularly Turner syndrome and mosaicism, which represent one of the classic models of female hypergonadotropic hypogonadism. Other factors include the FMR1 premutation and a growing number of variants in genes involved in meiosis, DNA repair, chromosomal stability, oocyte survival and follicular differentiation. A family history of very early menopause, unexplained amenorrhea or infertility of ovarian origin is therefore an epidemiological and historical finding of considerable importance.

A second major risk determinant is iatrogenic injury. Chemotherapy, pelvic radiotherapy or total body irradiation, bone marrow transplantation, extensive ovarian surgery, bilateral removal of the gonads and gonadotoxic treatments for oncological or autoimmune diseases may cause permanent or severely limiting damage to the follicular reserve. Risk depends on age at exposure, cumulative dose, type of drug or radiation and initial ovarian reserve. In the modern epidemiology of hypergonadotropic hypogonadism, the relative importance of iatrogenic causes has therefore increased in parallel with improved survival among patients treated during childhood or young adulthood.

The autoimmune category is more difficult to quantify epidemiologically because no single marker directly and reliably identifies all immune-mediated forms. Nevertheless, the association with autoimmune adrenal insufficiency, autoimmune thyroiditis and polyglandular syndromes demonstrates that immune vulnerability constitutes a clinically genuine and relevant subgroup. Rare metabolic diseases, such as certain forms of galactosemia, and multisystem syndromic conditions should also be considered among the risk factors during development and reproductive life.

Finally, the clinical epidemiology of this condition is magnified by its long-term consequences. A woman who develops hypoestrogenism during adolescence or young adulthood accumulates many years of exposure to skeletal, cardiovascular and sexual risks. Female hypergonadotropic hypogonadism should therefore not be viewed solely as a diagnosis of amenorrhea or infertility, but as a chronic endocrine syndrome of growing epidemiological relevance throughout the fertile and postpubertal stages of a woman’s life.

Female hypergonadotropic hypogonadism results from a primary ovarian defect. Under physiological conditions, the ovary contains a finite follicular reserve that must be maintained, recruited and guided through maturation under the integrated control of FSH, LH, intraovarian factors and local paracrine signals. When the number of follicles becomes critically reduced, or when the remaining follicles fail to mature or secrete adequate amounts of estrogen and inhibin, negative feedback to the hypothalamus and pituitary gland decreases. The pituitary responds by increasing the secretion of FSH and, to a variable extent, LH, but this increase cannot correct the peripheral defect.

From an aetiological perspective, the most relevant causes can be divided into four major categories. The first comprises genetic and chromosomal forms, in which the damage may involve gonadal development, formation of the follicular pool, meiosis, DNA repair or oocyte survival. The second includes autoimmune forms, in which ovarian tissue is damaged within a broader context of endocrine immune dysregulation. The third consists of iatrogenic forms caused by pharmacological, radiation-induced or surgical gonadotoxicity. The fourth includes idiopathic cases, which remain numerous but probably conceal a substantial proportion of genetic causes that have not yet been fully defined.

In chromosomal forms, the classic pathogenic model is gonadal dysgenesis. Numerical or structural abnormalities of the X chromosome impair the development of ovarian tissue and its ability to preserve the oocyte reserve. The result is transformation of the gonad into a fibrous structure containing few or no follicles, with absent or markedly impaired steroidogenesis. In mosaicism, damage may be less severe and allow menarche, partial puberty or initial menstrual activity, but functional decline remains accelerated and biologically unstable.

In non-chromosomal genetic forms, pathogenesis often involves genes that regulate meiosis, DNA damage checkpoints, recombination, stability of synaptonemal complexes, replication or oocyte maturation. When these systems do not function correctly, oocytes undergo premature apoptosis or follicles arrest at critical stages of development. This results in quantitative follicular depletion or a condition of follicular dysfunction in which follicles are present but fail to provide adequate endocrine or ovulatory function.

< b>Autoimmune forms have a less clearly defined pathophysiology. In some cases, the main target appears to be the steroidogenic and theca cell compartments, with a relative increase in LH compared with FSH and initial partial preservation of ovarian reserve markers. In others, the entire follicular unit is progressively affected. The association with adrenal or 21-hydroxylase antibodies suggests a connection with autoimmune oophoritis, particularly in the context of polyglandular syndromes. Although direct confirmation is often difficult, the final mechanism remains loss of estrogen production and ovulatory function.

In iatrogenic forms, pathophysiology is dominated by toxic or ablative injury. Chemotherapeutic agents induce DNA breaks and oocyte death, radiation destroys the follicular reserve and stromal microenvironment, while ovarian surgery reduces residual tissue and may impair vascularisation. If the loss is extensive, overt hypergonadotropic hypogonadism develops rapidly. If the damage is incomplete, phases of intermittent function may persist before definitive insufficiency develops.

The systemic pathophysiology of hypoestrogenism is the common final pathway. Reduced estradiol impairs urogenital trophism, menstrual regularity, pubertal development, bone mineral density, sexual function and certain aspects of cardiovascular and neurovascular protection. Bone resorption predominates, menstrual cyclicity and ovulation are lost, while hot flushes, insomnia, mood disturbances, reduced sexual wellbeing and metabolic vulnerability emerge. Female hypergonadotropic hypogonadism is therefore the endocrine manifestation of primary ovarian dysfunction with systemic consequences extending far beyond reproduction alone.

The clinical presentation of female hypergonadotropic hypogonadism varies substantially according to the age at onset and the speed at which ovarian function is lost. If the defect is present before puberty or impairment is severe from the outset, the patient may present with absent pubertal development, limited breast development, absence of menarche or incomplete pubertal progression. When the follicular reserve becomes depleted after an initial period of normal gonadal activity, the condition presents with oligomenorrhea, secondary amenorrhea, infertility or symptoms of hypoestrogenism in a woman who was previously eumenorrhoeic.

During the medical history, chronological reconstruction of menstrual function is essential. The age at menarche, cycle regularity, onset of oligomenorrhea, duration of amenorrhea, any sporadic bleeding and the presence of associated symptoms should be clarified. In adult women, hot flushes, sweating, insomnia, irritability, reduced libido, vaginal dryness and dyspareunia are common. In progressively developing forms, these symptoms may initially be attributed to stress, weight loss, anxiety or previous contraception, resulting in delayed diagnosis.

The reproductive dimension is often prominent. Infertility may be the main reason for assessment, particularly when the ovary retains fluctuating residual activity sufficient to make the condition less apparent symptomatically. In gonadal dysgenesis or complete follicular destruction, however, the dominant issue is the failure to acquire or the premature loss of reproductive capacity. This has a substantial psychological impact and requires particularly careful clinical communication.

Findings on physical examination depend on the stage of life and the duration of hypoestrogenism. Adolescents may show limited breast development, delayed puberty, reduced estrogen-dependent trophism and, in some cases, syndromic features suggesting chromosomal abnormalities, such as short stature, webbed neck or other characteristics suggestive of Turner syndrome. Adult women with prolonged hypoestrogenism may have hypotrophic vaginal mucosa, discomfort during intercourse, reduced lubrication and indirect signs of skeletal fragility or muscular deconditioning.

The neuropsychological and sexual component is common but underestimated. Sleep disturbances, emotional lability, a sense of loss, impaired quality of life, relationship difficulties and body-related distress may accompany both adolescent and young adult forms. Premature and unexpected loss of ovarian function is not experienced merely as a laboratory abnormality, but as a major life event with important consequences for identity and relationships.

Over the long term, untreated female hypergonadotropic hypogonadism increases the risk of osteopenia, osteoporosis, reduced peak bone mass in early-onset forms, worsening genitourinary trophism and increased cardiovascular risk. Its clinical expression therefore extends beyond amenorrhea. It represents a chronic estrogen deficiency that profoundly affects multiple biological systems and should be interpreted as a systemic endocrine syndrome.

Female hypergonadotropic hypogonadism should be suspected in every adolescent with absent or incomplete pubertal progression and in every woman younger than the usual age of menopause who presents with amenorrhea, persistent oligomenorrhea or infertility associated with symptoms of hypoestrogenism. It is not necessary to wait for complete absence of menstruation before investigating because many patients pass through a phase of intermittent ovarian dysfunction in which sporadic or irregular bleeding may incorrectly delay diagnostic reasoning.

Suspicion should increase when the clinical history includes hot flushes, sleep disturbances, vaginal dryness, pain during intercourse, reduced libido or a substantial deterioration in general wellbeing. At a young age, these symptoms are sometimes considered unlikely or attributed to other causes, but their association with menstrual dysfunction strongly suggests estrogen deficiency. Even a patient with few symptoms and prolonged amenorrhea requires assessment because skeletal and reproductive damage may already be occurring.

Particular attention should be given to high-risk settings. A history of chemotherapy, radiotherapy, ovarian surgery, partial gonadectomy, autoimmune endocrine disease, a family history of early menopause, unexplained amenorrhea or known genetic disease requires a very low threshold for suspicion. In adolescents, suspicion is high in the presence of short stature, a phenotype suggestive of Turner syndrome, delayed or absent puberty and growth patterns inconsistent with normal pubertal maturation.

It is also necessary not to confuse this condition too readily with functional hypothalamic amenorrhea, the effects of hormonal contraception or polycystic ovary syndrome. When the clinical context is not fully consistent with a central or functional cause, hormonal testing should be performed without delay. The most frequent error is not excessive suspicion, but delayed assessment of a young woman who already has findings suggestive of ovarian insufficiency.

Finally, clinical suspicion becomes particularly urgent when the patient wishes to conceive because diagnostic delay may lead to the loss of an opportunity for timely reproductive counselling. Even in patients without an immediate desire for pregnancy, early recognition remains essential to halt the systemic effects of hypoestrogenism and establish replacement therapy appropriate to biological risk and age.

The diagnosis of female hypergonadotropic hypogonadism requires confirmation that the endocrine defect is ovarian rather than central. The first step is therefore to document low estradiol associated with elevated FSH and LH in the context of amenorrhea, oligomenorrhea or absent puberty. This pattern indicates that the pituitary gland is appropriately but ineffectively stimulating a gonad that can no longer respond. Diagnostic reasoning should always begin with this pathophysiological relationship.

According to the Society for Endocrinology, evaluation of female hypogonadism of ovarian origin requires integration of clinical findings with a compatible biochemical profile, avoiding both overdiagnosis based on a single measurement and the opposite error of minimising prolonged amenorrhea in a young patient.

Diagnostic assessment of female hypergonadotropic hypogonadism

• Documentation of amenorrhea, marked menstrual irregularity or absent pubertal development in a compatible clinical context.
• Demonstration of persistently low estradiol, often below approximately 200 pmol/L, associated with elevated FSH and generally elevated LH.
• Exclusion of the main alternative causes of amenorrhea, particularly pregnancy, hyperprolactinemia, hypothalamic-pituitary disorders and functional or pharmacological conditions.
• Aetiological assessment using a targeted medical history, karyotype, FMR1 testing, autoimmune evaluation and pelvic imaging when indicated.

First-line tests therefore include beta-hCG, FSH, LH, estradiol, TSH and prolactin. Their purpose is not only to confirm hypoestrogenism, but also to identify the anatomical level of the defect. Elevated FSH with low estradiol indicates an ovarian cause, while low or inappropriately normal gonadotropins suggest a central form. In patients who are taking or have recently discontinued hormone therapy or contraceptives, interpretation should be cautious because these treatments may conceal amenorrhea and alter the laboratory profile.

Once the hypergonadotropic phenotype has been established, the second level is aetiological investigation. In forms that are not clearly iatrogenic, karyotyping is essential to identify X chromosome abnormalities and mosaicism. Testing for the FMR1 premutation is recommended because it represents one of the best documented genetic causes. When a syndromic condition is suspected, family history is significant or the clinical presentation is atypical, broader genetic investigation may be appropriate after specialist counselling.

< b>Autoimmune assessment should be targeted. In apparently idiopathic forms, testing for 21-hydroxylase antibodies or adrenal cortex antibodies is particularly relevant because positivity may indicate a risk of autoimmune adrenal insufficiency and suggest immune-mediated oophoritis. Thyroid function should always be assessed, while clinical judgement should determine whether investigations should be extended to other endocrine glands according to symptoms and context.

< b>Pelvic ultrasound complements the assessment but does not establish the diagnosis on its own. It may show small ovaries, a low antral follicle count or, in some cases, anatomy that appears less impaired than the endocrine profile would suggest. In adolescents with suspected gonadal dysgenesis, imaging also describes the internal genital structures and completes the morphological and functional assessment. In adults, its main value is to support clinical judgement and assist reproductive planning.

Finally, diagnosis must always culminate in an appropriate differential diagnosis. Functional hypothalamic amenorrhea, pituitary deficiencies, hyperprolactinemia, medication effects, pregnancy, certain forms of gonadal dysgenesis with specific syndromic features and conditions in which amenorrhea and hypoestrogenism do not result from primary ovarian insufficiency should be excluded. Only after these distinctions have been made can the condition be accurately defined as female hypergonadotropic hypogonadism and translated into an appropriate treatment and follow-up plan.

The classification of female hypergonadotropic hypogonadism has practical value because it links the endocrine phenotype to its cause, age at onset and prognostic profile. The first distinction separates congenital from acquired forms. Congenital forms include gonadal dysgenesis, chromosomal abnormalities and genetic defects that prevent normal development or maintenance of ovarian function. Acquired forms include spontaneous primary ovarian insufficiency, autoimmune damage and iatrogenic conditions secondary to medical or surgical treatments.

A second classification is temporal. Prepubertal forms present with absent or markedly delayed sexual development, whereas postpubertal forms emerge after a period of at least partially normal puberty and menstrual cyclicity. This distinction is essential because it changes therapeutic objectives and priorities. In adolescents, the first requirement may be pubertal induction and acquisition of peak bone mass. In adult women, management of amenorrhea, estrogen replacement, sexuality and fertility are often central.

From an aetiological perspective, chromosomal, monogenic, autoimmune, iatrogenic and idiopathic forms can be distinguished. Chromosomal forms tend to present early and are frequently associated with extragonadal manifestations. Forms caused by the FMR1 premutation or defects in meiotic and DNA repair genes may show variable expression and sometimes a family history. Autoimmune forms require surveillance for other endocrinopathies, while iatrogenic forms have a clearer causal history but raise specific issues regarding prevention and oncological and reproductive counselling.

A clinically useful classification concerns the presence of residual ovarian function. Some patients have complete gonadal inactivity, with no functional follicles and virtually no possibility of ovulation. Others retain intermittent function, with possible fluctuations in menstrual activity and rare occasional ovulations. This difference does not alter the hypergonadotropic nature of the condition, but it has important implications for contraceptive counselling, reproductive expectations and interpretation of symptoms over time.

< b>Severity should be assessed dynamically. It does not depend only on the degree of FSH elevation or the estradiol concentration, but on the combined effects of age at onset, duration of hypoestrogenism, pubertal or reproductive impairment, osteopenia, sexual symptoms, cardiovascular comorbidities and syndromic context. A patient with absent puberty or a long history of untreated hypoestrogenism has a clinically more severe condition than a patient identified during the early stages of ovarian dysfunction. This approach is essential because classification should determine the intensity of care rather than remain a purely nosological label.

Treatment of female hypergonadotropic hypogonadism is based on three objectives: adequately replacing the estrogen deficiency, preventing long-term complications and addressing reproductive issues realistically. In the great majority of patients, the cornerstone is hormone replacement therapy, which should be understood as replacement of an endocrine function lost too early rather than merely symptomatic treatment of natural menopause. Its purpose is to protect bone health, the cardiovascular system, urogenital trophism, sleep quality, sexual wellbeing and general health.

In adolescents with prepubertal onset, treatment should follow the principle of gradual pubertal induction. Low doses of estrogen are introduced and progressively increased to mimic physiological development and allow breast development, uterine maturation, harmonious growth and acquisition of bone mass. Once sufficient estrogenisation has been achieved, a progestogen is added in patients with a uterus to protect the endometrium. This pathway requires appropriate timing and careful monitoring because induction that is either too rapid or excessively delayed may impair skeletal, gynaecological and psychological outcomes.

In adult women, therapy is generally based on transdermal or oral estradiol, combined with a progestogen when the uterus is present. Guidelines emphasise that young women with hypogonadism may require fully replacement doses, often higher than those commonly used solely to control menopausal symptoms. The objective is not merely to eliminate hot flushes, but to restore estrogen exposure appropriate to the patient’s biological age. In many cases, treatment should continue at least until the expected age of natural menopause.

Treatment should also address sexual and urogenital health. Systemic therapy often improves dryness, discomfort and libido, although some women require the addition of local vaginal estrogen to achieve satisfactory restoration of tissue trophism. When libido remains reduced despite adequate estrogen control, the issue should be assessed by a specialist rather than dismissed because sexual health is a fundamental component of quality of life in patients with hypogonadism.

< b>Reproductive management requires clarity. In forms involving severe or established ovarian damage, oocyte donation generally offers the greatest reproductive effectiveness. In forms with intermittent residual function, spontaneous pregnancy may occasionally occur, but remains rare and unpredictable. This requires two complementary aspects of counselling. The patient should understand the marked reduction in reproductive potential, but should also be informed that contraception remains necessary when pregnancy is not desired, particularly during the early stages following diagnosis of some postpubertal 46,XX forms or after partially reversible iatrogenic damage.

In addition to hormone therapy, treatment should include lifestyle measures and prevention of complications, including regular physical activity, adequate calcium and vitamin D intake when indicated, smoking cessation, surveillance of cardiovascular risk factors and attention to mental health. In the presence of syndromic causes or specific comorbidities, management should be multidisciplinary. In patients with Turner syndrome, for example, treatment cannot be separated from cardiological, metabolic and general medical assessment, while autoimmune forms require broader endocrine surveillance.

Follow-up of female hypergonadotropic hypogonadism should be continuous and based on multiple objectives. The first is to verify that hormone therapy is genuinely replacement therapy rather than merely symptomatic. This requires regular reassessment of vasomotor symptoms, genitourinary comfort, sleep quality, pubertal development in adolescents, regularity of withdrawal bleeding when expected and treatment adherence. Apparent symptom control is not always sufficient to guarantee estrogen exposure appropriate to age.

Surveillance of bone health is central. Bone densitometry using DXA is particularly important in patients with prolonged exposure to hypoestrogenism, adolescents with delayed diagnosis, women with previously documented low bone mass or patients with poor treatment adherence. Monitoring should be individualised according to age, fracture risk and the underlying cause. In young women, the objective is not only to prevent bone loss, but also to permit optimal acquisition of peak bone mass whenever still possible.

< b>Cardiometabolic follow-up should not be neglected. Patients with untreated female hypogonadism have a less favourable cardiovascular profile, and guidelines emphasise the need to monitor blood pressure, body weight, lifestyle and associated risk factors. In specific subgroups, such as Turner syndrome, monitoring should be broader and include assessment for aortopathy, liver abnormalities, diabetes and other recognised complications of the syndrome.

< b>Aetiology-specific endocrine follow-up should be guided by the cause. Autoimmune forms require ongoing reassessment of adrenal and thyroid risk. In genetic forms, follow-up may include family counselling, periodic review of the molecular diagnosis and management of syndromic implications. In iatrogenic forms, the possibility of partial recovery of ovarian function in certain subgroups should be considered without underestimating the persistence of gonadal vulnerability.

< b>Contraceptive and reproductive management also requires ongoing assessment. In some forms, the probability of natural conception is virtually absent. In others, a small but genuine possibility of ovulation remains. Contraception should therefore be actively discussed when pregnancy is not desired. When the patient wishes to conceive, follow-up should be integrated with reproductive counselling, assessment of obstetric risk and a realistic definition of the available options.

Finally, follow-up should include the psychological and sexual dimensions. The impact of the diagnosis may persist even when the hormonal profile is adequately corrected. High-quality monitoring should therefore extend beyond laboratory tests and assess mental wellbeing, adaptation to therapy, body image, relationships and the need for psychological or psychosexual support. This is particularly important in adolescents and young women facing a diagnosis that prematurely alters development, fertility and self-image.

The prognosis of female hypergonadotropic hypogonadism depends on the cause, age at onset, promptness of diagnosis and quality of hormone replacement. The condition is not generally an acute emergency, but it has major prognostic significance because it causes additional years of hypoestrogenism. When treated early and monitored correctly, many of its consequences can be substantially reduced. When recognition is delayed or therapy is inadequate, the burden of complications progressively increases.

The most immediate complication in the natural history is reproductive impairment. In severe or complete forms, the potential for spontaneous conception is extremely low. In forms with residual ovarian function, fertility remains markedly reduced and unpredictable. This biological uncertainty represents an important aspect of the prognosis perceived by the patient because it affects family planning, relationship decisions and the need for assisted reproduction.

< b>Skeletal complications result directly from chronic estrogen deficiency. In forms beginning during adolescence, the main problem may be failure to achieve adequate peak bone mass. In forms developing during young adulthood, accelerated loss of bone mineral density predominates. Both situations increase the long-term risk of osteopenia, osteoporosis and fractures. Skeletal prognosis depends substantially on how promptly adequate estrogen replacement is initiated.

< b>Cardiovascular complications are of increasing importance. Premature hypoestrogenism is associated with a less favourable risk profile and, when untreated, increased cardiovascular morbidity. The mechanism is multifactorial and involves endothelial function, arterial compliance, lipid metabolism, body fat distribution and interactions with traditional risk factors. In certain syndromes, such as Turner syndrome, cardiovascular risk is also influenced by specific structural abnormalities that further worsen prognosis.

< b>Urogenital, sexual and psychological complications are common and may persist if not actively addressed. Vaginal dryness, dyspareunia, reduced libido, insomnia, depressed mood, anxiety and impaired quality of life are not secondary consequences of the diagnosis, but integral components of the disease. The best prognosis is achieved when these aspects are recognised early and incorporated into the treatment plan, rather than reducing management to biochemical normalisation alone.

Finally, prognosis also depends on the aetiological context. In syndromic or autoimmune forms, the patient may be exposed to extragonadal complications requiring specific surveillance. In iatrogenic forms, the endocrine disorder often occurs within the history of a major oncological or systemic disease and must therefore be considered within a broader clinical trajectory. Overall, female hypergonadotropic hypogonadism is a condition with substantial endocrine and systemic impact, but its prognosis can be markedly improved when diagnosis is early, the cause is correctly established and treatment provides adequate and continuous hormonal replacement.